Information Provided By:
Fly News Breaks for March 19, 2019
BA, YUM, IRBT, VRTX, IMGN
Mar 19, 2019 | 10:04 EDT
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ImmunoGen (IMGN) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying the failure of Forward I is a "meaningful setback" for the mirvetuximab development program. 2. Vertex (VRTX) downgraded to Market Perform from Outperform at SVB Leerink with analyst Geoffrey Porges citing the slower ramp of the company's cystic fibrosis products in Europe, the already high expectations priced into the stock and the limited near-term opportunities and catalysts from the company's pipeline. 3. iRobot (IRBT) downgraded to Hold from Buy at Needham with analyst James Ricchiuti stating the market appears to be pricing in expectations of "meaningful upside" to the company's 2019 guidance after the run-up in its stock price this year. 4. Yum! Brands (YUM) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe saying the 9% year-to-date run in shares leaves little upside to estimates. 5. Boeing (BA) downgraded to Hold from Buy at Argus with analyst John Eade stating that he believes company management has not been particularly proactive in its response to two fatal crashes involving the 737 Max jet. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For IMGN;VRTX;IRBT;YUM;BA From the Last 2 Days
IRBT
Mar 28, 2024 | 09:50 EDT
After Walmart (WMT) and Vizio (VZIO) pulled and refiled their notification under the Hart-Scott-Rodino Act Wednesday, Dealreporter told its readers that the move "may have investors wondering if this could become another Amazon (AMZN) and iRobot (IRBT) situation," contacts tell The Fly. While the M&A-focused publication said "there are traces of that same dynamic here," it added that "this pull-and-refile suggests this deal is on stronger footing than AMZN-IRBT," according to contacts. The news service sees "a genuine chance that this deal could get a prolonged look from regulators due to some of the similar dynamics at play compared to IRBT and AMZN," it reportedly said.
BA
Mar 28, 2024 | 06:35 EDT
Citi lowered the firm's price target on Boeing to $252 from $263 and keeps a Buy rating on the shares. The analyst says the fundamental outlook for commercial aerospace and Boeing has not changed as demand for new aircraft remains robust and there are only two major competitors that can fulfill it. While Boeing has stumbled on execution, this is not a permanent state, the analyst tells investors in a research note. Once fixed, Boeing's balance sheet repair will be the focus, as it should be, says Citi. The firm, however, sees no quick fix, and believes patience is required.